Vermillion, Inc, an Austin-based diagnostics company dedicated to gynecologic cancer and women’s health research, announced Dr. Judith K. Wolf as its new chief medical officer, starting next September.
According to information provided by the company, Wolf’s professional background and profile made her the “ideal fit for our expanding team of professionals,” said James LaFrance, Vermillion’s chairman, President and CEO, who also added that Wolf’s “exemplary career” and skills as a “tremendous asset” to Vermillion’s current research on OVA1®, a blood test that is conducted before a cirurgic procedure that helps to target the malignancy of an ovarian tumor using algorithms.
Over the last few years, Wolf has held several key leadership positions. She is the division chief of Surgical Oncology and vice chair of the Department of Oncology Services at the Banner MD Anderson Cancer Center in Arizona. She is also chairman of the Medical and Scientific Advisory Board of the National Ovarian Cancer Coalition, a fellow at the American College of Obstetrics and Gynecology and a member of the American Association of Cancer Research, Felix Rutledge Society, Society of Gynecologic Oncology and American Society of Clinical Oncology.
Wolf is an adjunct professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center, and a clinical professor of Division of Clinical Education at Arizona College of Osteopathic Medicine.
Part of her academic research is published in 94 co-authored peer-reviewed articles. She was also part of 11 research grants on gynecologic cancers and 84 protocols, and has been invited to present more than 50 conferences and many others scientific exhibitions and seminars.
Wolf graduated from Northeastern Ohio University’s College of Medicine and received her Masters in Biomedical Sciences at The University of Texas Health Science Center in Houston.
In related news, last April, Bionews Texas reported the nomination of Vermillion’s new president and CEO, James LaFrance.